Literature DB >> 29435079

MiR-34c induces apoptosis and inhibits the viability of M4e cells by targeting BCL2.

Rui Li1, Hongxia Zhang2, Xiling Zheng3.   

Abstract

The present study aimed to investigate microRNA (miR/miRNA)-34c expression and the association of miR-34c with B cell lymphoma 2 (BCL2) in M4e laryngeal carcinoma cell line. M4e laryngeal carcinoma cells were cultured and transfected with lenti-miR-34c or scramble miRNA for 72 h. Cell viability and the percentage of cells undergoing apoptosis of transfected cells were detected using MTT and Annexin V/allophycocyanin and propidium iodide assays, respectively. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blot analysis were performed to determine BCL2 mRNA and protein expression in transfected M4e cells. In addition, luciferase reporter assay was performed to identify whether BCL2 is a direct target of miR-34c. Transfection of lenti-miR-34c was able to significantly inhibit cell viability (P<0.01), increase the percentage of cells undergoing apoptosis (P<0.001) and downregulate BCL2 protein expression (P<0.01) in M4e cells. RT-qPCR data revealed that lenti-miR-34c transfection did not affect BCL2 mRNA expression. However, data from the luciferase reporter assay revealed that transfection with miR-34c negative control decreased luciferase activity in M4e cells co-transfected with pGL3-BCL2-MUT plasmid, compared with miR-34c inhibitor (P<0.01). Collectively, the results from the present study provided evidence that miR-34c may be involved in the pathogenesis of laryngeal cancer, and BCL2 may be negatively regulated by miR-34c in M4e cells.

Entities:  

Keywords:  B cell lymphoma 2; M4e cells; apoptosis; microRNA-34c

Year:  2017        PMID: 29435079      PMCID: PMC5778784          DOI: 10.3892/ol.2017.7640

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  23 in total

1.  MicroRNA-203 leads to G1 phase cell cycle arrest in laryngeal carcinoma cells by directly targeting survivin.

Authors:  Ka Bian; Jing Fan; Xiang Zhang; Xin-Wei Yang; Hua-Yu Zhu; Lei Wang; Jian-Yong Sun; Yan-Ling Meng; Peng-Cheng Cui; Shi-Yin Cheng; Jian Zhang; Jing Zhao; An-Gang Yang; Rui Zhang
Journal:  FEBS Lett       Date:  2012-02-01       Impact factor: 4.124

2.  microRNA and gene networks in human laryngeal cancer.

Authors:  Fengyu Zhang; Zhiwen Xu; Kunhao Wang; Linlin Sun; Genghe Liu; Baixu Han
Journal:  Exp Ther Med       Date:  2015-10-23       Impact factor: 2.447

3.  Retraction Notice to: A Pleiotropically Acting MicroRNA, miR-31, Inhibits Breast Cancer Metastasis.

Authors: 
Journal:  Cell       Date:  2015-04-09       Impact factor: 41.582

4.  MicroRNA-221 accelerates the proliferation of laryngeal cancer cell line Hep-2 by suppressing Apaf-1.

Authors:  Xin Sun; Bin Liu; Xu-Dong Zhao; Li-Yin Wang; Wen-Yue Ji
Journal:  Oncol Rep       Date:  2015-01-13       Impact factor: 3.906

5.  MicroRNA‑34a/c function as tumor suppressors in Hep‑2 laryngeal carcinoma cells and may reduce GALNT7 expression.

Authors:  Wei Li; Huiping Ma; Ji Sun
Journal:  Mol Med Rep       Date:  2014-01-30       Impact factor: 2.952

6.  Role of miR-34c in ketamine-induced neurotoxicity in neonatal mice hippocampus.

Authors:  Shu-e Cao; Jianmin Tian; Shengyang Chen; Xiaoran Zhang; Yongqiang Zhang
Journal:  Cell Biol Int       Date:  2015-02       Impact factor: 3.612

7.  MicroRNA-106b regulates the tumor suppressor RUNX3 in laryngeal carcinoma cells.

Authors:  Ying Xu; Kai Wang; Wei Gao; Chunming Zhang; Fuhui Huang; Shuxin Wen; Binquan Wang
Journal:  FEBS Lett       Date:  2013-08-01       Impact factor: 4.124

8.  Gene and protein expression of glucose transporter 1 and glucose transporter 3 in human laryngeal cancer-the relationship with regulatory hypoxia-inducible factor-1α expression, tumor invasiveness, and patient prognosis.

Authors:  Katarzyna Starska; Ewa Forma; Paweł Jóźwiak; Magdalena Bryś; Iwona Lewy-Trenda; Ewa Brzezińska-Błaszczyk; Anna Krześlak
Journal:  Tumour Biol       Date:  2014-11-21

9.  MicroRNA-16 inhibits glioma cell growth and invasion through suppression of BCL2 and the nuclear factor-κB1/MMP9 signaling pathway.

Authors:  Tian-Quan Yang; Xiao-Jun Lu; Ting-Feng Wu; Da-Dong Ding; Zhao-Hui Zhao; Gui-Lin Chen; Xue-Shun Xie; Bin Li; Yong-Xin Wei; Ling-Chuan Guo; Yu Zhang; Yu-Lun Huang; You-Xin Zhou; Zi-Wei Du
Journal:  Cancer Sci       Date:  2014-02-11       Impact factor: 6.716

10.  Galangin suppresses human laryngeal carcinoma via modulation of caspase-3 and AKT signaling pathways.

Authors:  Hai-Xu Wang; Chen Tang
Journal:  Oncol Rep       Date:  2017-06-29       Impact factor: 3.906

View more
  5 in total

1.  Protective Role of miR-34c in Hypoxia by Activating Autophagy through BCL2 Repression.

Authors:  Soyoung Kim; Jaeseok Han; Young-Ho Ahn; Chang Hoon Ha; Jung Jin Hwang; Sang-Eun Lee; Jae-Joong Kim; Nayoung Kim
Journal:  Mol Cells       Date:  2022-06-30       Impact factor: 4.250

2.  Up-regulation of miR-34c-5p inhibits nasopharyngeal carcinoma cells by mediating NOTCH1.

Authors:  Xin Xu; Haomin Yan; Le Zhang; Jing Liu; Yu Huang; Haoyu Cheng
Journal:  Biosci Rep       Date:  2020-06-26       Impact factor: 3.840

3.  miR-185-5p response to usnic acid suppresses proliferation and regulating apoptosis in breast cancer cell by targeting Bcl2.

Authors:  Elif Değerli; Vildan Torun; Demet Cansaran-Duman
Journal:  Biol Res       Date:  2020-05-04       Impact factor: 5.612

4.  MicroRNA-212-5p and its target PAFAH1B2 suppress vascular proliferation and contraction via the downregulation of RhoA.

Authors:  Gwi Ran Kim; Tingwei Zhao; Hae Jin Kee; Seung-Jung Kee; Myung Ho Jeong
Journal:  PLoS One       Date:  2021-03-24       Impact factor: 3.240

5.  Conserved MicroRNAs in Human Nasopharynx Tissue Samples from Swabs Are Differentially Expressed in Response to SARS-CoV-2.

Authors:  Ales Eichmeier; Tomas Kiss; Maria Kocanova; Eliska Hakalova; Milan Spetik; Jana Cechova; Boris Tichy
Journal:  Genes (Basel)       Date:  2022-02-14       Impact factor: 4.096

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.